Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Guidance on allergenicity assessment of genetically modified plants

EFSA Panel on Genetically Modified Organisms (GMO) et al. EFSA J. .

Abstract

This document provides supplementary guidance on specific topics for the allergenicity risk assessment of genetically modified plants. In particular, it supplements general recommendations outlined in previous EFSA GMO Panel guidelines and Implementing Regulation (EU) No 503/2013. The topics addressed are non-IgE-mediated adverse immune reactions to foods, in vitro protein digestibility tests and endogenous allergenicity. New scientific and regulatory developments regarding these three topics are described in this document. Considerations on the practical implementation of those developments in the risk assessment of genetically modified plants are discussed and recommended, where appropriate.

Keywords: GMO; allergenicity assessment; endogenous allergenicity; guidance; newly expressed proteins.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stepwise approach for risk assessment
Figure 2
Figure 2
Search for sequence identity
Figure 3
Figure 3
Q/E‐X1‐P‐X2 motif: possible combinations for the Q/E‐X1‐P‐X2 motif found in the large majority of identified immunogenic gluten‐derived epitopes. It was noted that, while position 1 is always either glutamic acid (E) or glutamine (Q) and position 3 always consists of a proline (P), also positions 2 (X1) and 4 (X2) are restricted to certain amino acids
Figure 4
Figure 4
Endogenous allergenicity workflow for the selection of relevant allergens in soybean
Figure A.1
Figure A.1
Shown is a side view of two peptides, one a gliadin T‐cell epitope (top panel) while the other is a peptide derived from a self‐antigen (lower panel). The side chains of the amino acids that point downwards anchor the peptide to the HLA‐DQ‐molecule, the upward‐pointing amino acids can be contacted by the T‐cell receptor. Even though the peptide share some sequence similarity (P at p1, L at P7, P at p8, large amino acid at p2), there are several features that are predicted to prohibit a functional interaction between a gliadin specific T‐cell receptor and the self‐peptide, like an overall different conformation and the presence of a large amino acids at p5 (Q) instead of the much smaller proline (P) in the gliadin peptide (taken from Wiesner et al., 2008)
Figure B.1
Figure B.1
Illustrative examples of in vitro gastrointestinal test conditions and proposed gastrointestinal conditions for the interim phase
Figure B.2
Figure B.2
Example of possible scenarios resulting from the in vitro digestibility tests and subsequent data interpretation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Cell-cultivated aquatic food products: emerging production systems for seafood.
    Goswami M, Ovissipour R, Bomkamp C, Nitin N, Lakra W, Post M, Kaplan DL. Goswami M, et al. J Biol Eng. 2024 Aug 7;18(1):43. doi: 10.1186/s13036-024-00436-1. J Biol Eng. 2024. PMID: 39113103 Free PMC article. Review.
  • Assessment of genetically modified maize DP910521 (application GMFF-2021-2473).
    EFSA Panel on Genetically Modified Organisms (GMO); Mullins E, Bresson JL, Dalmay T, Dewhurst IC, Epstein MM, Firbank LG, Guerche P, Hejatko J, Naegeli H, Moreno FJ, Nogué F, Rostoks N, Sánchez Serrano JJ, Savoini G, Veromann E, Veronesi F, Ardizzone M, De Sanctis G, Dumont AF, Gennaro A, Gómez Ruiz JÁ, Grammatikou P, Goumperis T, Lenzi P, Lewandowska A, Camargo AM, Neri FM, Piffanelli P, Raffaello T, Xiftou K. EFSA Panel on Genetically Modified Organisms (GMO), et al. EFSA J. 2024 Aug 1;22(8):e8887. doi: 10.2903/j.efsa.2024.8887. eCollection 2024 Aug. EFSA J. 2024. PMID: 39099615 Free PMC article.
  • Assessment of genetically modified maize MON 95275 (application GMFF-2022-5890).
    EFSA Panel on Genetically Modified Organisms (GMO); Mullins E, Bresson JL, Dalmay T, Dewhurst IC, Epstein MM, Firbank LG, Guerche P, Hejatko J, Naegeli H, Moreno FJ, Nogué F, Rostoks N, Sánchez Serrano JJ, Savoini G, Veromann E, Veronesi F, Ardizzone M, De Sanctis G, Silvia F, Dumont AF, Gennaro A, Gómez Ruiz JÁ, Grammatikou P, Goumperis T, Kagkli DM, Lenzi P, Lewandowska A, Camargo AM, Neri FM, Piffanelli P, Raffaello T, Xiftou K. EFSA Panel on Genetically Modified Organisms (GMO), et al. EFSA J. 2024 Aug 1;22(8):e8886. doi: 10.2903/j.efsa.2024.8886. eCollection 2024 Aug. EFSA J. 2024. PMID: 39099613 Free PMC article.
  • New developments in biotechnology applied to microorganisms.
    EFSA Panel on Genetically Modified Organisms (GMO); Mullins E, Bresson JL, Dewhurst IC, Epstein MM, Firbank LG, Guerche P, Hejatko J, Moreno FJ, Naegeli H, Nogué F, Rostoks N, Sánchez Serrano JJ, Savoini G, Veromann E, Veronesi F, Cocconcelli PS, Glandorf D, Herman L, Jimenez Saiz R, Ruiz Garcia L, Aguilera Entrena J, Gennaro A, Schoonjans R, Kagkli DM, Dalmay T. EFSA Panel on Genetically Modified Organisms (GMO), et al. EFSA J. 2024 Jul 22;22(7):e8895. doi: 10.2903/j.efsa.2024.8895. eCollection 2024 Jul. EFSA J. 2024. PMID: 39040572 Free PMC article.
  • Assessment of genetically modified maize MON 89034 × 1507 × MON 88017 × 59122 and 8 out of 10 of its subcombinations for renewal authorisation under Regulation (EC) No 1829/2003 (dossier GMFF-2022-9170).
    EFSA Panel on Genetically Modified Organisms (GMO); Mullins E, Bresson JL, Dalmay T, Dewhurst IC, Epstein MM, Firbank LG, Guerche P, Hejatko J, Moreno FJ, Naegeli H, Nogué F, Rostoks N, Sánchez Serrano JJ, Savoini G, Veromann E, Veronesi F, Camargo AM, Goumperis T, Lenzi P, Piffanelli P, Raffaello T. EFSA Panel on Genetically Modified Organisms (GMO), et al. EFSA J. 2024 Apr 29;22(4):e8715. doi: 10.2903/j.efsa.2024.8715. eCollection 2024 Apr. EFSA J. 2024. PMID: 38686342 Free PMC article.
See all "Cited by" articles

References

    1. Abadie V, Sollid LM, Barreiro LB and Jabri B, 2011. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annual Review of Immunology, 29, 493–525. - PubMed
    1. van Bergen J, Mulder CJ, Mearin ML and Koning F, 2015. Local communication among mucosal immune cells in patients with celiac disease. Gastroenterol, 148, 1187–1194. - PubMed
    1. Codex Alimentarius , 2003. Foods derived from modern biotechnology. Codex Alimentarius Commission, Joint FAO/WHO Food Standards Programme, Rome.
    1. Codex Alimentarius , 2009. Foods derived from modern biotechnology. Codex Alimentarius Commission, Joint FAO/WHO Food Standards Programme, Rome.
    1. Comino I, de Lourdes Moreno M and Sousa C, 2015. Role of oats in celiac disease. World Journal of Gastroenterology, 21, 11825–11831. - PMC - PubMed

LinkOut - more resources

-